HIV/AIDS
Latest news
33 articles · 20 / page
Elevated Heart Failure Risk in People With HIV: Insights from the REPRIEVE Trial
The REPRIEVE trial reveals higher heart failure incidence in people with HIV, particularly among women, Black participants in high-income regions, and those with hypertension or obesity. Traditional risk factors, not HIV-specific markers, w
Scaling Tobacco Cessation in HIV Care: National Quitlines as an Effective Alternative to Resource-Intensive Interventions
A landmark pragmatic randomized controlled trial in Vietnam reveals that proactive Quitline referrals are as effective as nurse-led counseling and nicotine replacement therapy for smoking cessation among people living with HIV, offering a s
Next-Day HIV Viral Load Results Improve Time to Care for People Living with HIV but Show Limited Impact on Prevention Linkage
This randomized clinical trial explored if next-day HIV viral load results improve linkage to care. While overall linkage rates remained unchanged, the intervention significantly accelerated care initiation for individuals already living wi
Tailored Implementation of Systems Navigation and Psychosocial Counselling to Enhance HIV Care Engagement among People Who Inject Drugs in Viet Nam: Evidence from a Cluster-Randomised Trial
A tailored approach to implementing systems navigation and psychosocial counselling significantly improved intervention fidelity and viral suppression among people with HIV who inject drugs in Viet Nam, compared to a standard strategy, high
High Viral Suppression with TLD in PEPFAR Programs — But Resistance and Adherence Signals Require Targeted Action
A multinational prospective cohort found high viral suppression after switching or initiating tenofovir–lamivudine–dolutegravir (TLD), but emergent dolutegravir-resistance was detected in a small subgroup with prior virological failure and
Dolutegravir + Lamivudine Is Non‑Inferior to Bictegravir/FTC/TAF for Maintenance Therapy at 48 Weeks: PASO‑DOBLE Randomised Trial
In PASO‑DOBLE, switching virologically suppressed adults to dolutegravir/lamivudine maintained viral suppression at 48 weeks and was non‑inferior to switching to bictegravir/emtricitabine/tenofovir alafenamide, supporting shared decision‑ma
Early Clinical Evaluation of Novel Broadly Neutralising Monoclonal Antibodies for HIV-1: Safety, Pharmacokinetics, and Neutralisation Profiles of N6LS, PGDM1400LS, and PGT121.414.LS
This review summarizes early-phase clinical trials assessing the safety, pharmacokinetics, and neutralisation activity of three innovative broadly neutralising monoclonal antibodies—N6LS, PGDM1400LS, and PGT121.414.LS—for HIV-1 prevention a
Infant Safety After In-Utero Exposure to Dapivirine Ring or Oral PrEP: 12‑Month Findings from MTN‑042/DELIVER
In a randomized phase 3b trial of pregnant women using the dapivirine vaginal ring or daily oral TDF/FTC for HIV prevention, 12‑month infant follow‑up showed no product‑related serious or grade 3+ adverse events and no HIV transmissions, su
Once‑Daily Dolutegravir/Lamivudine Fixed‑Dose Tablets Achieve Robust Pediatric Exposures and Reassuring Safety in the D3/PENTA 21 PK Sub‑Study
A nested PK and safety sub‑study of D3/PENTA 21 shows once‑daily DTG/3TC dispersible and film‑coated fixed‑dose tablets deliver adequate drug exposures across WHO weight bands in children 2–
Dolutegravir from Birth: PETITE‑DTG Shows Safe, Targeted Neonatal Dosing for Term Newborns
First randomized neonatal PK/safety data show 5 mg dolutegravir (dispersible tablet or oral film) every 48 hours for two weeks, then daily to day 28, achieves target troughs with acceptable safety in term infants born to mothers on dolutegr
A 21‑Valent Adult Pneumococcal Conjugate Vaccine (V116) Is Immunogenic and Well Tolerated in People Living with HIV: Results from STRIDE‑7
In STRIDE‑7, the adult‑specific 21‑valent conjugate vaccine V116 produced robust opsonophagocytic responses across all 21 serotypes and had a favorable tolerability profile in adults living with HIV, supporting broader serotype coverage com
Very Early Neonatal ART Enables ART‑Free HIV‑1 Remission in Some Children: Clinical Insights from IMPAACT P1115
IMPAACT P1115 shows that initiating combination ART within 48 hours of birth can enable sustained ART‑free HIV‑1 remission for 48+ weeks in a subset of children with in‑utero infection, but careful selection, close monitoring and standardiz
Dapivirine Ring and Oral PrEP in Pregnancy: MTN-042/DELIVER Shows Infant Safety Through 12 Months
A randomized phase 3b trial found no infant safety signals attributable to in-utero exposure to the dapivirine vaginal ring or oral tenofovir–emtricitabine PrEP over 12 months of follow-up, supporting use of both options for HIV prevention
Can Modafinil Break the Sleep–Mood Cycle in People Living with HIV?
Sleep disorders and depression are common in people living with HIV. Modafinil may improve daytime sleepiness, fatigue and cognition—especially for OSA-related EDS or augmentation in depression—but HIV-specific RCT data and ART interaction
Breaking the Cycle: How Modafinil Offers Hope for Sleep and Mood Disorders in HIV Patients
Sleep disturbances and mood disorders profoundly affect people living with HIV. Modafinil emerges as a promising therapy addressing daytime sleepiness, depression, and cognitive challenges, improving quality of life.
Nucleoside Reverse Transcriptase Inhibitors: A Novel Therapeutic Avenue Against Inflammaging and Age-Related Diseases
NRTIs, traditionally used in HIV and HBV treatment, demonstrate promising anti-inflammatory effects that may reduce the incidence of age-related diseases by inhibiting inflammaging processes associated with endogenous retroelements.
Accelerated Epigenetic Aging in HIV: Insights from a Systematic Review
Systematic review evidence supports accelerated epigenetic aging in people living with HIV compared to uninfected individuals, highlighting the need for further research considering antiretroviral therapy and confounding factors.
Long-Term Health Risks in HIV Patients with Immune Non-Response Despite Antiretroviral Therapy
Immune non-response despite ART in people with HIV significantly increases risk of both AIDS-defining and non-AIDS-defining comorbidities, underscoring the need for enhanced risk assessment beyond CD4+ T-cell counts.
Evolving Dermatologic Landscape in HIV: Prevalence, Incidence, and Risk Factors in the Modern ART Era from the DC Cohort
Despite advances in antiretroviral therapy, dermatologic diseases remain prevalent in people with HIV, with incidence declining yet significant disparities persisting related to immune status, demographics, and structural factors.
Understanding Motivations and Barriers in Donation-Based HIV/STI Interventions: Insights from a Systematic Review
This review synthesizes motivations, facilitators, and barriers of donation-based interventions in HIV/STI research, revealing key factors that enhance access to services through prosocial behaviors in diverse global settings.
Browse by specialty
Open language-specific specialty feeds and department pages.